PerkinElmer to Acquire Antibody and Reagent Leader BioLegend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/19/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Medifast launches Trilivy, replacing its Optavia brand
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
PerkinElmer (PKI) PT Raised to $175 at Stifel Following EPS and BioLegend Deal
July 27, 2021 6:18 AM EDTStifel analyst Daniel Arias raised the price target on PerkinElmer (NYSE: PKI) to $175.00 (from $155.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, PKI announced another acquisition (the company's 7th announced since Horizon in Nov '20 - though by far the... More
